The effect of etanercept on cardiac transplant recipients: A study of TNFα antagonism and cardiac allograft hypertrophy

Guillermo Torre, Cynthia K. Wallace, James B. Young, Michael M. Koerner, Vinay Thohan, Susan McRee, Roberta C. Bogaev

Research output: Contribution to journalArticle

13 Scopus citations

Abstract

Cardiac allograft hypertrophy is associated with persistent expression of cardiac tumor necrosis factor (TNF)-α. We investigated whether TNFα antagonism would impact allograft hypertrophy. EFECT (EFfect of Etanercept on Cardiac Transplantation) was a randomized, controlled, double-blind trial evaluating the effect of etanercept versus placebo treatment immediately posttransplant. The primary end-point was change in left ventricular (LV) mass after 6 months. Secondary endpoints included degree of collagen deposition at 6 months and incidence of adverse events. Forty-nine patients were randomized to either etanercept or placebo. LV mass increased significantly in both arms at 6 months, with a smaller increase in the etanercept group (19% vs. 33%, P=ns). Myocardial collagen content increased in the placebo, but not the etanercept, group (+39.8%, P<0.08 vs. -7.0%, P=NS). Allograft hypertrophy develops posttransplant with a corresponding increase in extracellular matrix. Etanercept appeared to decrease LV hypertrophy by decreasing extracellular matrix deposition.

Original languageEnglish (US)
Pages (from-to)480-483
Number of pages4
JournalTransplantation
Volume84
Issue number4
DOIs
StatePublished - Aug 2007

Keywords

  • Cardiac transplant
  • Etanercept
  • Hypertrophy
  • Tumor necrosis factor alpha

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Fingerprint Dive into the research topics of 'The effect of etanercept on cardiac transplant recipients: A study of TNFα antagonism and cardiac allograft hypertrophy'. Together they form a unique fingerprint.

Cite this